BioVentrix Overview
- Year Founded
-
2003
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
IPO
- (Cancelled)
- Latest Deal Amount
-
$17M
- Investors
-
8
BioVentrix General Information
Description
Developer of surgical equipment designed to improve and expand the treatment for congestive heart failure. The company's equipment improves cardiac function by restoring the size, volume and resulting function of the left ventricle in heart failure patients caused by ischemic cardiomyopathy, enabling physicians to be provided with innovative technology that corrects the anatomical damage created by congestive heart failure to slow the progression of this debilitating and fatal disease.
Contact Information
Website
bioventrix.comCorporate Office
- 120 Forbes Boulevard
- Suite 125
- Mansfield, MA 02048
- United States
Corporate Office
- 120 Forbes Boulevard
- Suite 125
- Mansfield, MA 02048
- United States
BioVentrix Timeline
BioVentrix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 19. IPO | 14-Oct-2026 | $17M | Cancelled | Generating Revenue/Not Profitable | ||
| 18. Later Stage VC | 29-Mar-2024 | Completed | Generating Revenue | |||
| 17. Later Stage VC (Series A) | 03-Apr-2023 | Completed | Generating Revenue | |||
| 16. Later Stage VC | 05-Apr-2022 | Completed | Generating Revenue | |||
| 15. Later Stage VC | 10-Jan-2022 | Completed | Generating Revenue | |||
| 14. Later Stage VC | 25-Nov-2020 | Completed | Generating Revenue | |||
| 13. Debt - PPP | 14-Apr-2020 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series A1) | 23-Jul-2019 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 30-Jun-2017 | $14.5M | $97.2M | Completed | Generating Revenue | |
| 10. Later Stage VC (Series A) | 08-Dec-2015 | $14M | $82.7M | Completed | Generating Revenue |
BioVentrix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BioVentrix Comparisons
Industry
Financing
Details
BioVentrix Competitors (9)
One of BioVentrix’s 9 competitors is Cardiac Dimensions, a Venture Capital-Backed company based in Kirkland, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cardiac Dimensions | Venture Capital-Backed | Kirkland, WA | ||||
| CorWave | Venture Capital-Backed | Clichy, France | ||||
| HighLife | Venture Capital-Backed | Paris, France | ||||
| Foldax | Venture Capital-Backed | Salt Lake City, UT | ||||
| Atricure | Formerly VC-backed | Mason, OH |
BioVentrix Patents
BioVentrix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4416740-A1 | Device and methods for monitoring heart function for treatment of congestive heart failure and other conditions | Pending | 15-Oct-2021 | ||
| US-20250005759-A1 | Device and methods for monitoring heart function for treatment of congestive heart failure and other conditions | Pending | 15-Oct-2021 | ||
| WO-2023064525-A1 | Device and methods for monitoring heart function for treatment of congestive heart failure and other conditions | Inactive | 15-Oct-2021 | ||
| EP-4216828-B1 | Pericardial inflation catheter and systems | Active | 24-Sep-2020 | ||
| EP-4216828-A1 | Pericardial inflation catheter and systems and methods employing same | Active | 24-Sep-2020 | A61B17/3478 |
BioVentrix Signals
BioVentrix Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Squarepoint Capital | Hedge Fund | Minority | ||
| Angel (individual) | Minority | |||
| Psilos Group Managers | Venture Capital | Minority | ||
| Double D Venture | Venture Capital | Minority |
BioVentrix Acquisitions (1)
BioVentrix’s most recent deal was a Merger/Acquisition with MateraCor. The deal was made on 27-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MateraCor | 27-Jan-2022 | Merger/Acquisition | Therapeutic Devices |
BioVentrix FAQs
-
When was BioVentrix founded?
BioVentrix was founded in 2003.
-
Where is BioVentrix headquartered?
BioVentrix is headquartered in Mansfield, MA.
-
What is the size of BioVentrix?
BioVentrix has 7 total employees.
-
What industry is BioVentrix in?
BioVentrix’s primary industry is Surgical Devices.
-
Is BioVentrix a private or public company?
BioVentrix is a Private company.
-
What is BioVentrix’s current revenue?
The current revenue for BioVentrix is .
-
How much funding has BioVentrix raised over time?
BioVentrix has raised $214M.
-
Who are BioVentrix’s investors?
Cormorant Asset Management, Squarepoint Capital, , Psilos Group Managers, and Double D Venture are 5 of 8 investors who have invested in BioVentrix.
-
Who are BioVentrix’s competitors?
Cardiac Dimensions, CorWave, HighLife, Foldax, and Atricure are some of the 9 competitors of BioVentrix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process